The use of CAR T-cell therapy has transformed outcomes for relapsed or refractory B-cell malignancies, but access to it remains extremely limited in some countries. Cartogene Therapeutics Pvt Ltd. aimed to address this need by in-licensing CGT-19, a CD19 CAR T construct from Vector Biomed Inc.